Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.

(2022) Thierry Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

(2021) E. A. Rozeman et al.   NATURE MEDICINE

Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

(2021) Huabin Hu et al.   Lancet Gastroenterology & Hepatology

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

(2020) Mallika Lala et al.   EUROPEAN JOURNAL OF CANCER

FOxTROT: neoadjuvant FOLFOX chemotherapy with or without panitumumab (Pan) for patients (pts) with locally advanced colon cancer (CC).

(2020) Jenny F. Seligmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer

(2020) Kaysia Ludford et al.   JNCI-Journal of the National Cancer Institute

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

(2020) Myriam Chalabi et al.   NATURE MEDICINE

Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series

(2020) Zhening Zhang et al.   EJSO

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

(2020) Thierry André et al.   LANCET ONCOLOGY

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

(2018) Wui-Jin Koh et al.   Journal of the National Comprehensive Cancer Network

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer

(2017) Salah-Eddin Al-Batran et al.   JAMA Oncology

Mismatch Repair Deficiency, Microsatellite Instability, and Survival

(2017) Elizabeth C. Smyth et al.   JAMA Oncology

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes

(2016) Kristine R. Broglio et al.   JAMA Oncology

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study

(2015) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is microsatellite instability a prognostic marker in gastric cancer?: A systematic review with meta-analysis

(2014) Yoon Young Choi et al.   JOURNAL OF SURGICAL ONCOLOGY

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

(2012) Apar Pataer et al.   Journal of Thoracic Oncology

Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

(2011) Gordon Hutchins et al.   JOURNAL OF CLINICAL ONCOLOGY

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial

(2007) Sarah Zohar et al.   Contemporary Clinical Trials